Rajeev Kumar, MD, Rocky Mountain Movement Disorders Center, Englewood, CO, and Ann Morgan, PhD, Annexon Biosciences, discuss new techniques for improving CNS delivery and distribution of Huntington’s disease therapies. One challenge with intrathecal treatment is that it may not effectively deliver the compound to the whole brain uniformly. Therefore, alternative delivery routes should be considered, such as intracerebroventricular delivery. Alternatively, a systemic delivery, either orally or intravenously, could provide uniform delivery of the therapy and address the whole body and brain. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr Morgan is an employee of Annexon Biosciences.
Dr Kumar is a consultant for Annexon Biosciences, and his institution receives funding from Annexon Biosciences.